Drug trial offers hope to patients with advanced colorectal cancer

August 27, 2012

A new drug treatment could offer hope to patients with advanced colorectal cancer who were intolerant of or did not respond to standard treatments, according to an article published in the Lancet Oncology.

The drug – called TAS-102 – was tested on 169 patients in Japan with inoperable, metastatic (spreading) colorectal cancer. The patients had already undergone several rounds of standard chemotherapy, to no effect, or were intolerant of standard drug treatments (which include , , and a group of drugs known as fluoropyrimidines).

Researchers found that, compared to placebo, patients treated with TAS-102 experienced improved survival time, reduced risk of death and better overall disease control, leading to hopes that the drug might one day be used as an effective treatment for advanced inoperable colorectal cancer.

Patients who received TAS-102 had a median overall survival of 9 months, as compared to 6.6 months for the . The TAS-102 group were also 44% less likely to die during the trial period than those given placebo.

Importantly, TAS-102 appears to be relatively safe, being well tolerated by most patients. While some patients experienced adverse reactions to the drug (mostly blood disorders), in all cases they were able to resume treatment after the had been addressed.

Colorectal cancer accounts for around 10% of all cancer cases, and is the fourth-leading cause of cancer-related deaths worldwide. There are currently no clinically proven treatment options available for patients with advanced, inoperable colorectal cancer who do not respond to, or are intolerant of, the standard drug treatments for the disease.

According to lead author Dr Takayuki Yoshino, of the National Cancer Center Hospital East in Kashiwa, Chiba, Japan, "Treatments that confer a in patients with heavily pretreated metastatic colorectal cancer are urgently needed. Our results show that TAS-102 has a promising efficacy and an easily manageable safety profile for a group of patients who have virtually no other treatment options available to them."

In a linked Comment, Dr Alberto Sobrero of the Ospedale San Martino in Genoa, Italy, welcomes the results, while emphasising that further work will be needed to confirm the results, adding that "With the assumption that the results represent the true effect of TAS-102, a new important advance in the treatment of colorectal will have been made."

Explore further: Drug improves survival of colorectal cancer patients, trial results show

More information: www.thelancet.com/journals/lan … (12)70345-5/abstract

Related Stories

Drug improves survival of colorectal cancer patients, trial results show

January 18, 2012
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented ...

Chemotherapy and radiation given together could help elderly patients with lung cancer live longer

May 21, 2012
Despite more than two-thirds of lung cancer cases being diagnosed in people 65 years or older, there have been few trials of treatments in this age group, and it is not known if the standard treatment for patients with inoperable ...

Merck KGaA suffers setback on cancer drug

July 5, 2012
German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Zaltrap approved for advanced colorectal cancer

August 4, 2012
(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.